Literature DB >> 8565584

Plasmacytoma development in mice injected with silicone gels.

M Potter1, S Morrison.   

Abstract

Silicone gels derived from commercially obtained implants induce plasmacytomas in 60-70% of highly susceptible BALB/cAn.DBA/2-Idh1-Pep3 congenic mice. In contrast, dimethylpolysiloxane (DMPS) silicone oils with viscosities of 5, 1000 and 12,500 cs fail to elicit these tumors. 1000 cs vinylmethylpolysiloxane is also inactive. Silicone gels, in contrast to the oils, induce a highly inflammatory silicone granuloma. Silicone gels contain chemical components not found in the oils. The chemical component responsible for inducing the permissive environment for plasmacytoma formation has not yet been identified. Silicone gels are well tolerated for long periods of time in mice without adverse effects other than plasmacytoma formation. The response to different gel preparations varies; some are associated with relatively rapid formation of plasmacytomas resembling that seen with pristane, while in others the plasmacytoma formation is extended nearly over a two year period.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8565584     DOI: 10.1007/978-3-642-85226-8_43

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  5 in total

1.  Assessment of all-trans retinoic acid (ATRA) efficacy as a single agent in primary lymphoid neoplasia.

Authors:  N Swaminathan; G Lopez-Berestein; S Rudikoff
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

2.  Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1.

Authors:  S Zhang; E S Ramsay; B A Mock
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

Review 3.  The immunopathology of siliconosis. History, clinical presentation, and relation to silicosis and the chemistry of silicon and silicone.

Authors:  D R Shanklin; D L Smalley
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

4.  Tonic interferon restricts pathogenic IL-17-driven inflammatory disease via balancing the microbiome.

Authors:  Isabelle J Marié; Lara Brambilla; Doua Azzouz; Ze Chen; Gisele V Baracho; Azlann Arnett; Haiyan S Li; Weiguo Liu; Luisa Cimmino; Pratip Chattopadhyay; Gregg Silverman; Stephanie S Watowich; Bernard Khor; David E Levy
Journal:  Elife       Date:  2021-08-11       Impact factor: 8.140

5.  Serum proteins and paraproteins in women with silicone implants and connective tissue disease: a case-control study.

Authors:  Gyorgy Csako; Rene Costello; Ejaz A Shamim; Terrance P O'Hanlon; Anthony Tran; Daniel J Clauw; H James Williams; Frederick W Miller
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.